Effect of Remote Cognitive Intervention in Patients With Parkinson's Disease During the COVID-19 Pandemic
- Conditions
- Parkinson DiseaseCOVID-19Mild Cognitive Impairment
- Interventions
- Other: Cognitive digital treatment
- Registration Number
- NCT05476302
- Lead Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
- Brief Summary
Retrospective study to evaluate the effect of a remote cognitive-rehabilitative intervention during the Covid outbreak in subjects with Parkinson's disease.
- Detailed Description
Mild cognitive impairment is frequent among people with Parkinson's disease. Cognitive training seems effective on cognitive status and for mitigating anxiety and depression. With COVID-19 outbreak, such therapeutic interventions were delivered online. This retrospective study was aimed at evaluating the effectiveness of an online cognitive treatment, carried out in COVID times and based on the Parkinson's-Adapted Cognitive Stimulation Therapy, on cognitive domains and mood in 18 older people with Parkinson's disease.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
- Parkinson disease: Hoehn & Yahr's scale: 1-3 based on the UK PD Society Brain Bank
- mild cognitive impairment
- no cognitive training between March and October 2020
- presence of a family caregiver to access and use the online platform
- other neurological diseases
- deep brain stimulation
- schizophrenia
- depression
- sensory deprivations that could interfere with the treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cognitive digital treatment Cognitive digital treatment Cognitive digital treatment in patients with Parkinson's disease
- Primary Outcome Measures
Name Time Method changes in cognitive status This evaluation was performed in the pre-COVID-19 period, at the beginning of the remote treatment (8 months from the pre-COVID evaluation), and at the end of the remote treatment (7 weeks from the start of the treatment) The Mini Mental State Examination (MMSE) was used to evaluate the cognitive status.The test consists of 2 parts: language (time orientation, registration and attention) and performance (recall, response to written/verbal commands, sriting ability and reproduction of complex polygons); the total score can range from 0 to 30, with a higher score indicating better function.
- Secondary Outcome Measures
Name Time Method changes in cognitive domains This evaluation was performed in the pre-COVID-19 period, at the beginning of the remote treatment (8 months from the pre-COVID evaluation), and at the end of the remote treatment (7 weeks from the start of the treatment) The Addembrooke's Cognitive Examination Battery (ACE-R) was used to evaluate the cognitive domains. The ACE-R consists of six components evaluating separate cognitive domains. A maximum score of 100 is weighted as follows: orientation (10), attention (8), memory(35), verbal fluency (14), language (28), and visuospatialability (5).
changes in thymic state This evaluation was performed in the pre-COVID-19 period, at the beginning of the remote treatment (8 months from the pre-COVID evaluation), and at the end of the remote treatment (7 weeks from the start of the treatment) The Geriatric Depression Scale-15 items (GDS-15 items) was used to evaluate the tymic state.This instrument evaluated depressive symptoms using yes/no answers. Scores range between 0 and 15 points. Higher scores indicate more severe depressive symptoms.
Trial Locations
- Locations (1)
IRCCS INRCA Hospital
🇮🇹Ancona, Italy